Prime Medicine (PRME) Competitors $5.12 +0.47 (+10.11%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$5.14 +0.02 (+0.39%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME vs. ARQT, ANIP, HRMY, IDYA, DYN, BEAM, RXRX, ADPT, TVTX, and MESOShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Arcutis Biotherapeutics (ARQT), ANI Pharmaceuticals (ANIP), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), Dyne Therapeutics (DYN), Beam Therapeutics (BEAM), Recursion Pharmaceuticals (RXRX), Adaptive Biotechnologies (ADPT), Travere Therapeutics (TVTX), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors Arcutis Biotherapeutics ANI Pharmaceuticals Harmony Biosciences IDEAYA Biosciences Dyne Therapeutics Beam Therapeutics Recursion Pharmaceuticals Adaptive Biotechnologies Travere Therapeutics Mesoblast Arcutis Biotherapeutics (NASDAQ:ARQT) and Prime Medicine (NYSE:PRME) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability. Do insiders and institutionals believe in ARQT or PRME? 70.4% of Prime Medicine shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 22.7% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor ARQT or PRME? In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Prime Medicine. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 6 mentions for Prime Medicine. Arcutis Biotherapeutics' average media sentiment score of 1.07 beat Prime Medicine's score of 0.81 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, ARQT or PRME? Arcutis Biotherapeutics has higher revenue and earnings than Prime Medicine. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$196.54M10.80-$140.04M-$0.75-23.61Prime Medicine$4.96M138.89-$198.13M-$1.56-3.28 Do analysts recommend ARQT or PRME? Arcutis Biotherapeutics currently has a consensus price target of $19.80, indicating a potential upside of 11.80%. Prime Medicine has a consensus price target of $8.92, indicating a potential upside of 74.15%. Given Prime Medicine's higher probable upside, analysts plainly believe Prime Medicine is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Is ARQT or PRME more profitable? Prime Medicine has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -35.40%. Arcutis Biotherapeutics' return on equity of -62.62% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-35.40% -62.62% -25.16% Prime Medicine N/A -107.87%-74.97% Which has more volatility & risk, ARQT or PRME? Arcutis Biotherapeutics has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.38, meaning that its share price is 138% more volatile than the S&P 500. SummaryArcutis Biotherapeutics beats Prime Medicine on 9 of the 17 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$689.02M$294.43M$5.78B$21.57BDividend YieldN/AN/A5.74%3.50%P/E Ratio-2.50N/A76.4830.17Price / Sales138.89423.92536.5477.21Price / CashN/A22.4437.1724.62Price / Book3.7410.1213.754.58Net Income-$198.13M-$115.81M$3.29B$1.00B7 Day Performance25.80%1.55%1.57%1.52%1 Month Performance58.02%7.33%6.83%5.96%1 Year Performance30.95%-14.71%80.77%14.24% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.866 of 5 stars$5.12+10.1%$8.92+74.2%+28.6%$689.02M$4.96M-2.50234News CoverageOptions VolumeHigh Trading VolumeARQTArcutis Biotherapeutics2.3079 of 5 stars$17.33+1.0%$19.80+14.3%+70.3%$2.08B$196.54M-23.11150ANIPANI Pharmaceuticals4.0706 of 5 stars$95.20-0.2%$88.25-7.3%+59.7%$2.07B$614.38M-123.63600Analyst ForecastAnalyst RevisionHRMYHarmony Biosciences4.5685 of 5 stars$35.83-0.4%$51.00+42.3%-14.9%$2.06B$714.73M11.56200Positive NewsIDYAIDEAYA Biosciences4.0045 of 5 stars$23.39-13.9%$45.77+95.7%-24.5%$2.05B$7M-6.1780Analyst ForecastGap UpHigh Trading VolumeDYNDyne Therapeutics3.7516 of 5 stars$13.30-6.5%$34.07+156.1%-59.5%$2.02BN/A-3.45100Positive NewsGap UpBEAMBeam Therapeutics3.2167 of 5 stars$19.94-4.5%$48.45+143.0%-1.6%$2.02B$63.52M-4.43510Gap UpHigh Trading VolumeRXRXRecursion Pharmaceuticals2.185 of 5 stars$4.62+0.2%$7.25+56.9%-28.7%$2.01B$64.51M-2.60400ADPTAdaptive Biotechnologies3.4788 of 5 stars$12.54-2.4%$12.38-1.3%+198.7%$1.91B$178.96M-15.29790Positive NewsTVTXTravere Therapeutics3.197 of 5 stars$21.20-2.0%$33.43+57.7%+68.6%$1.89B$233.18M-10.39460MESOMesoblast1.7221 of 5 stars$14.55+1.1%$18.00+23.7%+154.4%$1.86B$17.20M0.0080Positive NewsGap Up Related Companies and Tools Related Companies Arcutis Biotherapeutics Alternatives ANI Pharmaceuticals Alternatives Harmony Biosciences Alternatives IDEAYA Biosciences Alternatives Dyne Therapeutics Alternatives Beam Therapeutics Alternatives Recursion Pharmaceuticals Alternatives Adaptive Biotechnologies Alternatives Travere Therapeutics Alternatives Mesoblast Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
